Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Euroz Hartleys Rottnest Island Institutional Conference 2021
18 slides from Proteomics International Laboratories's conference presentation, Mar 9, 2021
Slide 1: ASX Release: Investor Presentation
ASX Release 9 March 2021 ASX code: PIQ Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at the Euroz Hartleys Institutional Conference to be held o
Slide 2: Investor Presentation - Building a Global Diagnostics Business
Investor Presentation Euroz Hartleys Rottnest Island Institutional Conference 9-11 March 2021 BUILDING A GLOBAL DIAGNOSTICS BUSINESS 1 ASX: PIQ Proteomics International Laboratories Ltd
Slide 3: Disclaimer
Disclaimer ASX:PIQ This Presentation is provided by Proteomics International Laboratories Ltd (ASX: PIQ, Proteomics International, Proteomics, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in d
Slide 4: Corporate Overview
Corporate Overview ASX:PIQ Proteomics International Laboratories Ltd (ASX: PIQ) is a medical CORPORATE SNAPSHOT – 05/03/2021 technology company at the forefront of predictive diagnostics ASX code PIQ and bioanalytical services Share Price A$1.12 DIAGNOSTICS Shares on issue (+ 7.7m options) 105m Prom
Slide 5: Board & Management
Board & Management ASX:PIQ South & Central America Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology Ltd, Hear
Slide 6: Promarker – Platform Technology
Promarker – Platform Technology ASX:PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 5
Slide 7: Predictive Test for Diabetic Kidney Disease
ASX:PIQ PREDICTIVE TEST FOR DIABETIC KIDNEY DISEASE 6
Slide 8: The Problem / The Solution
THE PROBLEM ➢ 1 in 3 adults with diabetes currently have chronic kidney disease (CKD) Nth America & Caribbean 50% ASX:PIQ UNDIAGNOSED Europe South & Central America South-East Asia Middle East & North Africa Western Pacific Africa Sth/Ctrl America ➢ There is no early warning - kidney function can fa
Slide 9: PromarkerD is Revenue Ready
PromarkerD is Revenue Ready ASX:PIQ The PromarkerD predictive test is poised to roll-out in markets globally Significant Unmet Need ✓ 463m adults have diabetes globally - 1 in 3 currently have DKD High Statistical Performance ✓ Peer reviewed publications – Clinical & Analytical validity proven Simpl
Slide 10: PromarkerD in the Clinic
PromarkerD in the Clinic ASX:PIQ EXISTING STANDARD-OF-CARE CANNOT PREDICT DIABETIC KIDNEY DISEASE (DKD) PromarkerD tested on over 5,000 patients in 4 yr clinical studies A simple blood test that measures three plasma proteins combined with three clinical factors (age, cholesterol, eGFR); advanced cl
Slide 11: PromarkerD - Route To Market
PromarkerD - Route To Market ASX:PIQ OUT-LICENSING MODEL for IN VITRO DIAGNOSTIC TEST (IVD) Clinical Pathology Laboratories ▪ Immunoassay kit standard to clinical pathology ▪ PIQ licences test to be run in approved lab laboratories ▪ PIQ supplies the product to the lab at cost ▪ CE Mark (EU) approve
Slide 12: PromarkerD - Market Opportunity
PromarkerD - Market Opportunity ASX:PIQ Market assumptions: Proteomics International Patent Portfolio & Market Size ➢ Test is performed once per year per patient on average [Standard of care: High-risk patients are tested every 3-6 months; Low-risk every 2 years]. ➢ Test price of US $150 [based on s
Slide 13: Diagnostics Pipeline
Diagnostics Further Global Potential in New Markets Pipeline Employs the PromarkerTM technology platform to develop novel intellectual property Targeting new diagnostic tests in areas of significant unmet need Global markets and revenue potential The PromarkerTM research pipeline and typical timelin
Slide 14: Diagnostics in Development: Endometriosis
Diagnostics in Development: Endometriosis ASX:PIQ What Is Endometriosis? A debilitating condition in which tissue that normally lines the uterus grows outside the uterus (on the ovaries, fallopian tubes or the intestines) The most common symptoms are chronic pain and menstrual irregularities Diagnos
Slide 15: Promarker Timeline & Upcoming Milestones
Promarker™ Timeline & Upcoming Milestones Two year targets and achievements 2021 targets November 2018 June 2020 Additional Proteomics enters Licensing deals for Big pharma PromarkerD November 2019 PromarkerD with (Janssen) clinical collaboration with US diagnostic, CE Mark for study validates big p
Slide 16: PIQ: Value Inflection Points 2021
PIQ: Value Inflection Points 2021 EXCEPTIONAL GLOBAL OPPORTUNITY ✓ Cutting-edge technology & proven in-house diagnostics platform ✓ PromarkerD test de-risked, patented and rolling-out in easy-to-use, low cost format ✓ Scalable licensing model with high margins and accessible to diverse range of diag
Slide 17: Peer Comparison
Peer Comparison Market Share FY20 FY20 Net Stock Code Company Focus Capitalisation Price Revenue Profit/Loss DKD test based on AI and a combination of predictive blood- £632m + RENX.LSE 880p & based biomarkers, genetic factors and electronic health US$173m N/A US$9.3m loss Renalytix AI RNLX.US US$28
Slide 18: Contact
Contact ASX:PIQ Richard Lipscombe Dirk van Dissel Managing Director Corporate Advisor & Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au Kyle Moss Corporate Advisor Euroz